Literature DB >> 944211

Single - dose immunization of human subjects against tetanus.

K I Matveev, T I Sergeeva, E K Zarubina, Z L Minaeva.   

Abstract

A study was performed on human subjects to assess the effectiveness of single-dose immunization with 20 CU (1 ml) of adsorbed tetanus toxoid followed by revaccination with 10 CU (0.5 ml) 1 year later. Out of 1187 students, only those were selected for observation whose blood serum did not contain tetanus antitoxin (titre less than 0.001 IU/ml); this group counted 283 students. After administering the 20 CU (1 ml) of toxoid the antitoxin titre was repeatedly checked on days 10--15 and persons whose titre had risen to over 0.01 IU/ml were excluded from observation. The remaining 109 persons were tested for the antitoxin level 1 year later and revaccinated with 10 CU of tetanus toxoid. After 10--15 days their postrevaccination titre was determined. The single-dose immunization with 20 CU of tetanus toxoid in human subjects not given tetanus antigen previously was accompanied by a gradul rise in the antitoxin titre up to the protective level and its maintenance for 1 year (observation time) until revaccination. Revaccination with 10 CU of toxoid provided in 10--15 days a multiple (100--197fold) increase of the antitoxin titre, many times exceeding the protective level. The usefulness of transition to the shortened immunization scheme for tetanus prophylaxis of the adult population is discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 944211

Source DB:  PubMed          Journal:  J Hyg Epidemiol Microbiol Immunol        ISSN: 0022-1732


  2 in total

1.  Reduction of neonatal tetanus by mass immunization of non-pregnant women: duration of protection provided by one or two doses of aluminium-adsorbed tetanus toxoid.

Authors:  R E Black; D H Huber; G T Curlin
Journal:  Bull World Health Organ       Date:  1980       Impact factor: 9.408

2.  Should adult tetanus immunization be given as a single vaccination at age 65? A cost-effectiveness analysis.

Authors:  D J Balestra; B Littenberg
Journal:  J Gen Intern Med       Date:  1993-08       Impact factor: 5.128

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.